Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated SCC
Status:
Recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This pilot trial studies how rigsertib sodium works in treating patients with Recessive
Dystrophic Epidermolysis bullosa (RDEB) with locally advanced Squamous Cell Carcinoma (SCC).
Rigosertib may selectively target Epidermolysis bullosa (EB) cancer cells while leaving
normal EB cells unaffected.